Clinical data | |
---|---|
Other names | ZK-98734; ZK-734; 11β-(4-(Dimethylamino)phenyl)-17β-hydroxy-17α-((Z)-3-hydroxypropenyl)estra-4,9-dien-3-one |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C29H37NO3 |
Molar mass | 447.619 g·mol−1 |
3D model (JSmol) | |
| |
|
Lilopristone (INN) (developmental code names ZK-98734, ZK-734) is a synthetic, steroidal antiprogestogen with additional antiglucocorticoid activity which was developed by Schering and was patented in 1985.[1][2][3][4] It is described as an abortifacient and endometrial contraceptive.[1][4][5] The drug differs from mifepristone only in the structure of its C17α side chain, and is said to have much reduced antiglucocorticoid activity in comparison.[6]
[...] lilopristone, which differs from mifepristone only in the structure of the 17a side chain, is said to have a much reduced antiglucocorticoid activity (Neef et al., 1984).